Cisco stock dips as tech rally cools in final week of 2025
29 December 2025
1 min read

Cisco stock dips as tech rally cools in final week of 2025

NEW YORK, December 29, 2025, 12:16 ET — Regular session

  • Cisco was down 0.6% at $77.71 in late-morning trade, after touching $77.57 at the session low.
  • The technology sector pulled back with the Nasdaq-tracking QQQ and tech-sector XLK each down about 0.6%.
  • Investors are watching Fed minutes and weekly jobless claims later this week, ahead of Cisco’s next earnings call on Feb. 11. 1

Cisco Systems (CSCO.O) shares fell 0.6% to $77.71 in late-morning trading on Monday. The stock was down about 46 cents from its prior close.

The move came as U.S. stocks eased from recent highs to start the final three sessions of 2025, with heavyweight technology and artificial intelligence (AI) names giving back some of last week’s gains. 1

Broader markets were lower, with the S&P 500-tracking SPY down 0.5% and the Nasdaq-focused QQQ down 0.6%. The Technology Select Sector SPDR fund (XLK) was off about 0.7%.

“This is (not) the beginning of the end of the tech dominance, it’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford Trust. 1

Cisco traded between $77.57 and $78.31 on Monday, with volume at about 2.9 million shares by late morning.

Peers were mixed. Arista Networks rose 1.2%, while Hewlett Packard Enterprise fell 0.9% and Dell Technologies slid 1.1%.

In cybersecurity, Palo Alto Networks and Fortinet were both down about 0.9% as the broader tech complex weakened.

Some investors are still looking for a “Santa Claus rally” — a seasonal pattern where the S&P 500 often gains in the last five trading days of the year and the first two sessions in January — after a strong run for U.S. stocks in 2025. 1

Markets this week also face a lighter calendar and reduced liquidity, with U.S. markets closed on Thursday for New Year’s Day. 1

On the macro front, traders are watching minutes from the Federal Reserve’s last policy meeting and weekly jobless claims data for clues on the rate outlook that can sway tech valuations. 1

For Cisco, the next major catalyst is its quarterly earnings call on Wednesday, Feb. 11 at 4:30 p.m. ET, the company said in prepared remarks for its last results. 2

Cisco has told investors to expect fiscal 2026 revenue of $60.2 billion to $61.0 billion and adjusted earnings per share of $4.08 to $4.14, leaving traders focused on whether enterprise networking demand and AI-related infrastructure orders stay strong into year-end. 2

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
TMC stock drops 5% as NOAA’s seabed-mining deadlines come into focus
Previous Story

TMC stock drops 5% as NOAA’s seabed-mining deadlines come into focus

AAOI stock swings, then slips as investors refocus on 800G ramp
Next Story

AAOI stock swings, then slips as investors refocus on 800G ramp

Go toTop